Welcome to our dedicated page for Vsee Health SEC filings (Ticker: VSEEW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings and related disclosures for VSee Health, Inc. (Nasdaq: VSEE, VSEEW), a telehealth technology and services company in the health services sector. The company describes itself as delivering high-acuity virtual care solutions through a scalable, API-driven platform that integrates secure video, device data, and EHR connectivity.
Although specific forms are not listed here, VSee Health has referenced SEC reporting in its public communications. In connection with regaining compliance with Nasdaq Listing Rule 5550(b)(1), the Minimum Equity Rule, the company stated that it filed a pro forma balance sheet on Form 8-K/A reflecting capital transactions such as conversion of convertible notes into common stock, cash exercise and exchange of certain public warrants, and a private placement of common stock or pre-funded warrants with accompanying warrants.
On Stock Titan, users can review VSee Health’s historical and future SEC submissions as they become available, including current reports on Form 8-K that describe material events affecting its capital structure, listing status, or business. For a telehealth and digital health company, such filings can provide additional context on areas like financing arrangements, equity transactions, and other corporate actions that support its telehealth, remote patient monitoring, and digital health services.
AI-powered tools on this page summarize lengthy filings, highlight key sections, and make it easier to understand how reported events relate to VSee Health’s telehealth platform and Nasdaq Capital Market listing. Users can use these summaries to quickly identify important disclosures without reading every page of each filing.
VSee Health, Inc. entered into a high-interest note financing with an institutional investor. The company issued an 8% original issue discount secured promissory note with an aggregate principal amount of $271,739.13, which includes an original issue discount of $21,739.13. The note bears interest at 18% per annum and matures on December 8, 2026.
The company may prepay all or part of the note at 100% of the amount redeemed plus a 10% prepayment fee. If VSee receives proceeds from an equity line of credit with the same holder, it must repay the entire outstanding balance within two business days. The note is secured by certain company assets under a related security agreement.
VSee Health, Inc. entered into a high-interest note financing with an institutional investor. The company issued an 8% original issue discount secured promissory note with an aggregate principal amount of $271,739.13, which includes an original issue discount of $21,739.13. The note bears interest at 18% per annum and matures on December 8, 2026.
The company may prepay all or part of the note at 100% of the amount redeemed plus a 10% prepayment fee. If VSee receives proceeds from an equity line of credit with the same holder, it must repay the entire outstanding balance within two business days. The note is secured by certain company assets under a related security agreement.
VSee Health, Inc. entered into a Standby Equity Purchase Agreement with YA II PN, LTD., giving the company the right to sell up to $10 million of common stock over time. The arrangement runs until June 2, 2029, unless the full commitment is used or it is terminated earlier.
Shares sold under each Advance will be priced at 97% of the lowest daily VWAP over a three-day pricing period. VSee will issue 532,481 commitment shares and pay a $25,000 structuring fee from the first Advance. Issuances are capped at 9,715,140 shares, about 19.99% of pre-agreement outstanding shares, and the investor’s beneficial ownership is limited to 4.99%.
VSee Health, Inc. entered into a Standby Equity Purchase Agreement with YA II PN, LTD., giving the company the right to sell up to $10 million of common stock over time. The arrangement runs until June 2, 2029, unless the full commitment is used or it is terminated earlier.
Shares sold under each Advance will be priced at 97% of the lowest daily VWAP over a three-day pricing period. VSee will issue 532,481 commitment shares and pay a $25,000 structuring fee from the first Advance. Issuances are capped at 9,715,140 shares, about 19.99% of pre-agreement outstanding shares, and the investor’s beneficial ownership is limited to 4.99%.
VSee Health, Inc. agreed to sell all of the equity of its wholly owned subsidiary VSee Lab, Inc. to co-Chief Executive Officer and Chairman Milton Chen, effective May 31, 2026. In return, Chen will transfer to the company all 2,870,069 shares of VSee Health common stock he owns, which are treated as a stock repurchase.
Under the agreement, Chen is solely responsible for indebtedness and other liabilities of VSee Lab not paid at closing, while VSee Health remains responsible for liabilities tied to periods on or before the closing date, including most taxes. Concurrent with closing, Chen resigned as co-Chief Executive Officer and chairman; co-CEO Dr. Imoigele Aisiku became sole Chief Executive Officer and chairman.
Unaudited pro forma financials show how results would look without VSee Lab and its subsidiary. For 2025, revenue would decline from $14,618,184 to $7,302,954, while net loss would narrow from $14,712,850 to $9,972,749. For the quarter ended March 31, 2026, revenue would fall from $3,160,185 to $1,879,293 and net loss would narrow from $2,600,262 to $1,264,882.
VSee Health, Inc. agreed to sell all of the equity of its wholly owned subsidiary VSee Lab, Inc. to co-Chief Executive Officer and Chairman Milton Chen, effective May 31, 2026. In return, Chen will transfer to the company all 2,870,069 shares of VSee Health common stock he owns, which are treated as a stock repurchase.
Under the agreement, Chen is solely responsible for indebtedness and other liabilities of VSee Lab not paid at closing, while VSee Health remains responsible for liabilities tied to periods on or before the closing date, including most taxes. Concurrent with closing, Chen resigned as co-Chief Executive Officer and chairman; co-CEO Dr. Imoigele Aisiku became sole Chief Executive Officer and chairman.
Unaudited pro forma financials show how results would look without VSee Lab and its subsidiary. For 2025, revenue would decline from $14,618,184 to $7,302,954, while net loss would narrow from $14,712,850 to $9,972,749. For the quarter ended March 31, 2026, revenue would fall from $3,160,185 to $1,879,293 and net loss would narrow from $2,600,262 to $1,264,882.
VSee Health, Inc. director and Co-Chief Executive Officer Milton Chen reported an internal restructuring transaction. On May 31, 2026, he transferred 2,870,069 shares of Common Stock to VSee Health, Inc. as consideration under a Stock Purchase Agreement related to his purchase of all equity securities of VSee Lab, Inc. from the company. Following this transaction, his directly held VSee common stock position was reported as 0 shares.
VSee Health, Inc. director and Co-Chief Executive Officer Milton Chen reported an internal restructuring transaction. On May 31, 2026, he transferred 2,870,069 shares of Common Stock to VSee Health, Inc. as consideration under a Stock Purchase Agreement related to his purchase of all equity securities of VSee Lab, Inc. from the company. Following this transaction, his directly held VSee common stock position was reported as 0 shares.
VSee Health, Inc. reported first‑quarter 2026 revenue of $3.16 million, compared with $3.32 million in the prior‑year quarter. Gross margin was $1.20 million while operating expenses rose to $4.17 million, leading to a net operating loss of $2.97 million.
Net loss narrowed to $2.60 million versus $3.96 million a year earlier, helped by a $367,809 gain on extinguishment of financial liabilities and a $143,040 gain from changes in fair value of financial instruments. Basic and diluted loss per share was $0.05 on a weighted average of 47.9 million shares.
Cash declined to $1.35 million from $5.27 million at December 31, 2025, with operating activities using $2.45 million of cash in the quarter. The company ended the period with total assets of $19.0 million, liabilities of $12.7 million, and stockholders’ equity of $6.32 million, alongside an accumulated deficit of $85.0 million. Management states that recurring losses and liquidity conditions raise substantial doubt about VSee Health’s ability to continue as a going concern.
VSee Health, Inc. reported first‑quarter 2026 revenue of $3.16 million, compared with $3.32 million in the prior‑year quarter. Gross margin was $1.20 million while operating expenses rose to $4.17 million, leading to a net operating loss of $2.97 million.
Net loss narrowed to $2.60 million versus $3.96 million a year earlier, helped by a $367,809 gain on extinguishment of financial liabilities and a $143,040 gain from changes in fair value of financial instruments. Basic and diluted loss per share was $0.05 on a weighted average of 47.9 million shares.
Cash declined to $1.35 million from $5.27 million at December 31, 2025, with operating activities using $2.45 million of cash in the quarter. The company ended the period with total assets of $19.0 million, liabilities of $12.7 million, and stockholders’ equity of $6.32 million, alongside an accumulated deficit of $85.0 million. Management states that recurring losses and liquidity conditions raise substantial doubt about VSee Health’s ability to continue as a going concern.
VSee Health, Inc. Schedule 13G/A reports that Armistice Capital, LLC and Steven Boyd together beneficially own 4,861,392 shares, representing 9.99% of the outstanding common stock. The filing states Armistice Capital shares voting and dispositive power over those shares through its role as investment manager of Armistice Capital Master Fund Ltd.
The statement explains the Master Fund is the direct holder and that the Master Fund "specifically disclaims beneficial ownership" by reason of its inability to vote or dispose under its Investment Management Agreement. The amendment is signed by Steven Boyd on 05/15/2026.
VSee Health, Inc. Schedule 13G/A reports that Armistice Capital, LLC and Steven Boyd together beneficially own 4,861,392 shares, representing 9.99% of the outstanding common stock. The filing states Armistice Capital shares voting and dispositive power over those shares through its role as investment manager of Armistice Capital Master Fund Ltd.
The statement explains the Master Fund is the direct holder and that the Master Fund "specifically disclaims beneficial ownership" by reason of its inability to vote or dispose under its Investment Management Agreement. The amendment is signed by Steven Boyd on 05/15/2026.
VSee Health, Inc. files its annual report describing a telehealth software platform and high-acuity critical care services alongside significant losses and going‑concern risks. The company reported operating losses of $9,582,893 in 2025 and $62,150,845 in 2024, with an accumulated deficit of $82,416,723 as of December 31, 2025. Its auditor highlighted substantial doubt about VSee’s ability to continue as a going concern due to ongoing losses and negative operating cash flows.
VSee delivers configurable, no‑code and low‑code telehealth tools through VSee Lab and tele‑ICU and specialty physician services through iDoc, targeting hospital systems, ICUs, correctional facilities and other high‑acuity settings. Competition is intense from large telehealth vendors, EMR‑embedded tools and in‑house solutions. The company faces heavy regulatory exposure, including HIPAA, state privacy rules, anti‑kickback and self‑referral laws, False Claims Act risk and evolving Medicare/Medicaid telehealth reimbursement. VSee also depends heavily on a small number of major customers and approximately 93 board‑certified physicians within a 209‑person workforce.
VSee Health, Inc. files its annual report describing a telehealth software platform and high-acuity critical care services alongside significant losses and going‑concern risks. The company reported operating losses of $9,582,893 in 2025 and $62,150,845 in 2024, with an accumulated deficit of $82,416,723 as of December 31, 2025. Its auditor highlighted substantial doubt about VSee’s ability to continue as a going concern due to ongoing losses and negative operating cash flows.
VSee delivers configurable, no‑code and low‑code telehealth tools through VSee Lab and tele‑ICU and specialty physician services through iDoc, targeting hospital systems, ICUs, correctional facilities and other high‑acuity settings. Competition is intense from large telehealth vendors, EMR‑embedded tools and in‑house solutions. The company faces heavy regulatory exposure, including HIPAA, state privacy rules, anti‑kickback and self‑referral laws, False Claims Act risk and evolving Medicare/Medicaid telehealth reimbursement. VSee also depends heavily on a small number of major customers and approximately 93 board‑certified physicians within a 209‑person workforce.
Aisiku Imoigele reported acquisition or exercise transactions in this Form 4 filing.
VSee Health, Inc. director and Co-Chief Executive Officer Aisiku Imoigele reported receiving four quarterly equity awards of common stock under the company’s 2024 Incentive Plan, all dated March 23, 2026 and tied to 2025 quarters. The grants cover 128,342 shares at $0.37 per share, 78,689 shares at $0.61, 41,379 shares at $1.16, and 40,000 shares at $1.20, issued as stock compensation pursuant to his executive employment agreement.
Aisiku Imoigele reported acquisition or exercise transactions in this Form 4 filing.
VSee Health, Inc. director and Co-Chief Executive Officer Aisiku Imoigele reported receiving four quarterly equity awards of common stock under the company’s 2024 Incentive Plan, all dated March 23, 2026 and tied to 2025 quarters. The grants cover 128,342 shares at $0.37 per share, 78,689 shares at $0.61, 41,379 shares at $1.16, and 40,000 shares at $1.20, issued as stock compensation pursuant to his executive employment agreement.
O'SULLIVAN COLIN P. reported acquisition or exercise transactions in this Form 4 filing.
VSEE HEALTH, INC. director Colin P. O'Sullivan reported an award of 40,107 shares of common stock, granted under the company’s 2024 Incentive Plan as compensation for his board service for the quarter ended December 31, 2025.
The number of shares was based on the common stock closing price on December 31, 2025, and after this grant he directly owns 108,731 shares of VSEE common stock.
O'SULLIVAN COLIN P. reported acquisition or exercise transactions in this Form 4 filing.
VSEE HEALTH, INC. director Colin P. O'Sullivan reported an award of 40,107 shares of common stock, granted under the company’s 2024 Incentive Plan as compensation for his board service for the quarter ended December 31, 2025.
The number of shares was based on the common stock closing price on December 31, 2025, and after this grant he directly owns 108,731 shares of VSEE common stock.
METZGER SCOTT reported acquisition or exercise transactions in this Form 4 filing.
VSEE Health, Inc. director Scott Metzger received a grant of 40,107 shares of common stock at $0.374 per share. This equity award was issued under the company’s 2024 Incentive Plan as compensation for his service as a non-employee director for the quarter ended December 31, 2025.
After this grant, Metzger directly holds a total of 117,356 shares of VSEE Health common stock. The number of shares granted was determined using the common stock’s closing price on December 31, 2025.
METZGER SCOTT reported acquisition or exercise transactions in this Form 4 filing.
VSEE Health, Inc. director Scott Metzger received a grant of 40,107 shares of common stock at $0.374 per share. This equity award was issued under the company’s 2024 Incentive Plan as compensation for his service as a non-employee director for the quarter ended December 31, 2025.
After this grant, Metzger directly holds a total of 117,356 shares of VSEE Health common stock. The number of shares granted was determined using the common stock’s closing price on December 31, 2025.